News

Verastem Oncology Receives Fast-Track Designation for Avutometinib and Sotorasib Combination in NSCLC

1 Mins read

Boston-based biopharmaceutical company, Verastem Oncology, has announced that the US Food and Drug Administration (FDA) has granted their avutometinib and sotorasib combination a fast-track designation for the treatment of non-small cell lung cancer (NSCLC).

Fast-Track Designation for KRAS G12C-Mutant Metastatic NSCLC

The fast-track designation specifically applies to patients with KRAS G12C-mutant metastatic NSCLC who have previously undergone at least one systemic therapy and have not been treated with a KRAS G12C inhibitor before.

Accelerated Development and Review Process

The FDA’s fast-track designation aims to expedite the development and review of drugs that address serious or life-threatening conditions and fulfill unmet medical needs. This designation is expected to accelerate the overall timeline for the combination’s development.

Significance of the Combination

Verastem Oncology highlights the significance of this combination, as KRAS G12C is the most common KRAS mutation found in NSCLC. The advancement of this treatment approach offers potential new options for patients.

CEO’s Perspective

Chief Executive Dan Paterson expressed his optimism regarding this development, stating, “Given that KRAS G12C is the most common KRAS mutation in NSCLC, the advancement of the combination is important in understanding potential new treatment approaches.”

Related posts
News

North Korea Accused of Stealing Billions Through Cyberattacks to Fund Nuclear Program

3 Mins read
An international report reveals North Korea’s extensive cyber operations, detailing billions stolen through cryptocurrency theft, fake remote tech jobs, and malware, all…
News

The silent war: When virtual attacks inflict real-world devastation

3 Mins read
As digital transformation accelerates worldwide, cyberspace has become vital to the economy and society — but also a high-risk arena for data…
News

'Ether Caught Fire': ETH Surged as Capital Fled Bitcoin in Q3, CoinGecko Report Finds

2 Mins read
Ethereum (ETH) emerged as the frontrunner in crypto’s third-quarter recovery, leaving bitcoin (BTC) behind as capital flowed into altcoins, DeFi protocols, and…

Leave a Reply

Your email address will not be published. Required fields are marked *